Patient-specific neoantigen peptides presented on patient Human Leukocyte Antigen (Neoantigen-HLA complex)

Patient-specific neoantigen peptides presented on patient Human Leukocyte Antigen (HLA) are unique protein fragments resulting from somatic mutations within a patient's tumor cells. These mutations, which include single-nucleotide variants, insertions, deletions, and frameshifts, create novel amino acid sequences that are not present in the normal human proteome (Nature Reviews Cancer, 2017). When these mutated proteins are processed and displayed on the cell surface by the patient's own HLA molecules, they can be recognized by the immune system as foreign or non-self. This recognition is the fundamental basis for personalized cancer immunotherapies, such as mRNA-based vaccines and adoptive T-cell therapies, which aim to prime or expand T-cells to selectively target and eliminate tumor cells (NIH National Cancer Institute). Because these neoantigens are entirely specific to the tumor, they offer a high degree of therapeutic precision and a lower risk of off-target toxicity compared to traditional shared tumor antigens. However, the clinical application of these targets requires advanced bioinformatics for neoantigen prediction and rapid, individualized manufacturing processes to match the patient's unique tumor profile (PubMed: 29739818).

Other names

Tumor-specific neoantigensNeoepitopesPersonalized neoantigensTSNAsPeptide-MHC complexpMHC

Induction of a de novo T-cell response or expansion of existing neoantigen-specific T-cells that recognize and lyse tumor cells presenting the specific mutated peptide on HLA molecules.